Search
Results: 129
ANCA-associated vasculitis.
A Richard Kitching, Hans-Joachim Anders, Neil Basu, Elisabeth Brouwer, Jennifer Gordon, David R Jayne, Joyce Kullman, Paul A Lyons, Peter A Merkel, Caroline OS Savage, Ulrich Specks, Renate Kain
Sep 14, 2020
The anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs) are a group of disorders involving severe, systemic, small-vessel vasculitis and are characterized by the development of autoantibodies to the...
Complement inhibition in ANCA vasculitis.
David Jayne
Feb 21, 2020
A role for the alternative complement pathway has emerged in the understanding of ANCA vasculitis pathogenesis. Current therapies of ANCA vasculitis are limited by partial efficacy and toxicity and many patients pursue a...
ANCA C5a clinical trial complement Therapy Vasculitis Aniline Compounds Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Antibodies Monoclonal Clinical Trials Phase II as Topic Complement C5a Complement Inactivating Agents Complement Pathway Alternative Humans Neutrophil Activation Nipecotic Acids
Subclassifying ANCA-associated vasculitis
This editorial refers to Clinical impact of subgrouping
ANCA-associated vasculitis according to antibody
specificity beyond the clinicopathological classification,
Deshayes et al.
Adult-Onset ANCA-Associated Vasculitis in SAVI
Frederik Staels, Albrecht Betrains, Peter Doubel, Mathijs Willemsen, Vincent Cleemput, Steven Vanderschueren, Anniek Corveleyn, Isabelle Meyts, Ben Sprangers, Yanick J Crow, Stephanie Humblet-Baron, Adrian Liston, Rik Schrijvers
Nov 30, 2020
STING-associated vasculopathy with onset in infancy (SAVI) is an autosomal dominant disorder due to gain-of-function mutations in STING1, also known as TMEM173, encoding for STING. It was reported as a vasculopathy of infancy....
SAVI glomerulonephritis interferonopathy primary immunodeficiency vasculopathy Age of Onset Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Genetic Predisposition to Disease Heredity Heterozygote Humans Male Membrane Proteins Mutation Pedigree Phenotype Prognosis Vascular diseases Young Adult
COVID-19 and ANCA-associated vasculitis
Annette Bruchfeld, Andreas Kronbichler, Federico Alberici, Fernando C Fervenza, David RW Jayne, Mårten Segelmark, Vladimir Tesar, Wladimir M Szpirt
Nov 17, 2021
COVID-19 and ANCA-associated vasculitis - recommendations for vaccine preparedness and the use of rituximab.
Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status.
Paul A Lyons, James E Peters, Federico Alberici, James Liley, Richard M R Coulson, William Astle, Chiara Baldini, Francesco Bonatti, Maria C Cid, Heather Elding, Giacomo Emmi, Jörg Epplen, Loïc Guillevin, David R W Jayne, Tao Jiang, Iva Gunnarsson, Peter Lamprecht, Stephen Leslie, Mark A Little, Davide Martorana, Frank Moosig, Thomas Neumann, Sophie Ohlsson, Stefanie Quickert, Giuseppe A Ramirez, Barbara Rewerska, Georg Schett, Renato A Sinico, Wojciech Szczeklik, Vladimir Tesar, Damjan Vukcevic, Benjamin Terrier, Richard A Watts, Augusto Vaglio, Julia U Holle, Chris Wallace, Kenneth G C Smith
Dec 14, 2019
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare inflammatory disease of unknown cause. 30% of patients have anti-neutrophil cytoplasmic antibodies (ANCA) specific for myeloperoxidase (MPO). Here, we describe a...
ANCA-Associated Glomerulonephritis
Arda Göçeroğlu, Annelies E Berden, Marta Fiocco, Oliver Flossmann, Kerstin W Westman, Franco Ferrario, Gill Gaskin, Charles D Pusey, E Christiaan Hagen, Laure-Hélène Noël, Niels Rasmussen, Rüdiger Waldherr, Michael Walsh, Jan A Bruijn, David RW Jayne, Ingeborg M Bajema, European Vasculitis Society (EUVAS)
Feb 24, 2020
Relapse in ANCA-associated vasculitis (AAV) has been studied previously, but there are few studies on renal relapse in particular. Identifying patients at high risk of renal relapse may aid in optimizing clinical management. We...
Aged Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Antibodies Antineutrophil Cytoplasmic Chronic Disease Europe Female Follow-Up Studies Glomerular Filtration Rate glomerulonephritis Humans Incidence Kidney Kidney Failure Chronic Male Middle Aged Proportional Hazards Models Recurrence Regression Analysis Risk Factors Treatment Outcome
Long term azathioprine maintenance therapy in ANCA-associated vasculitis
Anoek AE de Joode, Jan Stephan F Sanders, Xavier Puéchal, Loic P Guillevin, Thomas F Hiemstra, Oliver Flossmann, Nils Rasmussen, Kerstin Westman, David R Jayne, Coen A Stegeman
Sep 10, 2018
OBJECTIVE: We studied whether in ANCA-associated vasculitis patients, duration of AZA maintenance influenced relapse rate during long-term follow-up. METHODS: Three hundred and eighty newly diagnosed ANCA-associated vasculitis...
ANCA EUVAS FVSG PR3 Azathioprine Granulomatosis with polyangiitis long-term follow-up Maintenance Vasculitis Adult Aged Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Antibodies Antineutrophil Cytoplasmic Azathioprine Disease-Free Survival Female Follow-Up Studies Granulomatosis with polyangiitis Humans Immunosuppressive Agents Kidney Diseases Maintenance Chemotherapy Male Microscopic Polyangiitis Middle Aged Myeloblastin Peroxidase Recurrence Time Factors Young Adult
Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status
Paul A Lyons, James E Peters, Federico Alberici, James Liley, Richard M. R. Coulson, William Astle, Chiara Baldini, Francesco Bonatti, Maria C Cid, Heather Elding, Giacomo Emmi, Jörg Epplen, Loïc Guillevin, David R. W. Jayne, Tao Jiang, Iva Gunnarsson, Peter Lamprecht, Stephen Leslie, Mark A. Little, Davide Martorana, Frank Moosig, Thomas Neumann, Sophie Ohlsson, Stefanie Quickert, Giuseppe A. Ramirez, Barbara Rewerska, Georg Schett, Renato A. Sinico, Wojciech Szczeklik, Vladimir Tesar, Damjan Vukcevic, Benjamin Terrier, Richard A Watts, Augusto Vaglio, Julia U Holle, Chris Wallace, Kenneth G. C. Smith, Mohammed Akil, Jonathan Barratt, Neil Basu, Adam S. Butterworth, Ian Bruce, Michael Clarkson, Niall Conlon, Bhaskar DasGupta, Timothy W. R. Doulton, Georgina Espígol-Frigolé, Oliver Flossmann, Armando Gabrielli, Jolanta Gasior, Gina Gregorini, Giuseppe Guida, José Hernández-Rodríguez, Zdenka Hruskova, Amy Hudson, Ann Knight, Peter Lanyon, Raashid Luqmani, Malgorzata Magliano, Angelo A. Manfredi, Christopher Marguerie, Federica Maritati, Chiara Marvisi, Neil J. McHugh, Eamonn Molloy, Allan Motyer, Chetan Mukhtyar, Leonid Padyukov, Alberto Pesci, Sergio Prieto-Gonzalez, Marc Ramentol-Sintas, Petra Reis, Dario Roccatello, Patrizia Rovere-Querini, Carlo Salvarani, Francesca Santarsia, Roser Solans-Laque, Nicole Soranzo, Jo Taylor, Julie Wessels, Jochen Zwerina
Nov 11, 2020
Abstract: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare inflammatory disease of unknown cause. 30% of patients have anti-neutrophil cytoplasmic antibodies (ANCA) specific for myeloperoxidase (MPO). Here, we...
The immunopathology of ANCA-associated vasculitis.
The small-vessel vasculitides are a group of disorders characterised by variable patterns of small blood vessel inflammation producing a markedly heterogeneous clinical phenotype. While any vessel in any organ may be involved...
ANCA-Associated Vasculitis
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) represents a group of small vessel vasculitides characterized by granulomatous and neutrophilic tissue inflammation, often associated with the production of...
ANCA associated vasculitis
ANCA associated vasculitis is a serious, very often recurrent disease that despite the current standard treatment with high-dose glucocorticoids and either cyclophosphamide or rituximab, patients have a nine-fold increased...
Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis
Rachel B Jones, Thomas F Hiemstra, Jose Ballarin, Daniel Engelbert Blockmans, Paul Brogan, Annette Bruchfeld, Maria C Cid, Karen Dahlsveen, Janak De Zoysa, Georgína Espigol-Frigolé, Peter Lanyon, Chen Au Peh, Vladimir Tesar, Augusto Vaglio, Michael Walsh, Dorothy Walsh, Giles Walters, Lorraine Harper, David Jayne, European Vasculitis Study Group (EUVAS)
Feb 06, 2019
OBJECTIVES: Cyclophosphamide induction regimens are effective for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), but are associated with infections, malignancies and infertility. Mycophenolate mofetil...
ANCA-associated vasculitis cyclophosphamide induction therapy mycophenolate Randomised trial Adolescent Adult Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Azathioprine Child cyclophosphamide Female Humans Immunosuppressive Agents Induction Chemotherapy Male Mycophenolic Acid Recurrence Treatment Outcome
ANCA-Associated Vasculitis
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) represents a group of small vessel vasculitides characterized by granulomatous and neutrophilic tissue inflammation, often associated with the production of...
Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis.
Alexandre Karras, Christian Pagnoux, Marion Haubitz, Kirsten de Groot, Xavier Puechal, Jan Willem Cohen Tervaert, Mårten Segelmark, Loic Guillevin, David Jayne, European Vasculitis Society
Feb 27, 2020
OBJECTIVES: A prospective randomised trial to compare two different durations of maintenance immunosuppressive therapy for the prevention of relapse in anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV)....
ANCA Azathioprine maintenance therapy Relapse Vasculitis Adult Aged Anti-Inflammatory Agents Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Antibodies Antineutrophil Cytoplasmic Azathioprine Creatinine cyclophosphamide Female Glomerular Filtration Rate Humans Immunosuppressive Agents Kidney Failure Chronic Maintenance Chemotherapy Male Middle Aged Prednisolone Prospective Studies Remission Induction Secondary Prevention Survival Rate Time Factors
A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS)
Mark E McClure, Seerapani Gopaluni, James Wason, Robert B Henderson, Andre van Maurik, Caroline CO Savage, Charles D Pusey, Alan D Salama, Paul A Lyons, Jacinta Lee, Kim Mynard, David R Jayne, Rachel B Jones, on behalf the COMBIVAS investigators
Mar 13, 2023
BACKGROUND: Sequential B cell-targeted immunotherapy with BAFF antagonism (belimumab) and B cell depletion (rituximab) may enhance B cell targeting in ANCA-associated vasculitis (AAV) through several mechanisms. METHODS: Study...
Avacopan for the Treatment of ANCA-Associated Vasculitis.
BACKGROUND: The C5a receptor inhibitor avacopan is being studied for the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. METHODS: In this randomized, controlled trial, we assigned patients with...
Administration Oral Aniline Compounds Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Azathioprine cyclophosphamide Double-Blind Method Drug Therapy Combination Female Glucocorticoids Humans Immunosuppressive Agents Kaplan-Meier Estimate Male Middle Aged Nipecotic Acids prednisone Receptor Anaphylatoxin C5a Recurrence Remission Induction Rituximab
A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS)
Mark E McClure, Seerapani Gopaluni, James Wason, Robert B Henderson, Andre van Maurik, Caroline C O Savage, Charles D Pusey, Alan D Salama, Paul A Lyons, Jacinta Lee, Kim Mynard, David R Jayne, Rachel B Jones
Apr 11, 2023
Background
Sequential B cell-targeted immunotherapy with BAFF antagonism (belimumab) and B cell depletion (rituximab) may enhance B cell targeting in ANCA-associated vasculitis (AAV) through several...
Vasculitis Rituximab belimumab ANCA Humans Immunosuppressive Agents Antibodies Antineutrophil Cytoplasmic Treatment Outcome Proteomics Randomized Controlled Trials as Topic Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Published by: Trials
The COVID-19 pandemic and ANCA-associated vasculitis - reports from the EUVAS meeting and EUVAS education forum.
Andreas Kronbichler, Duvuru Geetha, Rona M Smith, Allyson C Egan, Ingeborg M Bajema, Ulf Schönermarck, Alfred Mahr, Hans-Joachim Anders, Annette Bruchfeld, Maria C Cid, David RW Jayne
Jan 06, 2022
The Coronavirus Disease 2019 (COVID-19) pandemic influenced the management of patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. A paucity of data exists on outcome of patients with vasculitis...
Comparative efficacy and safety of alternative glucocorticoids regimens in patients with ANCA-associated vasculitis
Yingqi Xiao, Gordon Guyatt, Linan Zeng, David Rw Jayne, Peter A Merkel, Reed Ac Siemieniuk, Jared E Dookie, Tayler A Buchan, Muhammad Muneeb Ahmed, Rachel J Couban, Alfred Mahr, Michael Walsh
Mar 02, 2022
OBJECTIVE: To compare the efficacy and safety of alternative glucocorticoids (GCs) regimens as induction therapy for patients with antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis. DESIGN: Systematic review of...
Position paper
Xavier Bossuyt, Jan-Willem Cohen Tervaert, Yoshihiro Arimura, Daniel Blockmans, Luis Felipe Flores-Suárez, Loïc Guillevin, Bernhard Hellmich, David Jayne, J Charles Jennette, Cees GM Kallenberg, Sergey Moiseev, Pavel Novikov, Antonella Radice, Judith Anne Savige, Renato Alberto Sinico, Ulrich Specks, Pieter van Paassen, Ming-Hui Zhao, Niels Rasmussen, Jan Damoiseaux, Elena Csernok
Feb 24, 2020
Anti-neutrophil cytoplasmic antibodies (ANCAs) are valuable laboratory markers used for the diagnosis of well-defined types of small-vessel vasculitis, including granulomatosis with polyangiitis (GPA) and microscopic...
Proteinase-3 and myeloperoxidase serotype in relation to demographic factors and geographic distribution in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis.
Maria Weiner, Rune Bjørneklett, Zdenka Hrušková, Bruce Mackinnon, Caroline J Poulton, Leo Sindelar, Aladdin J Mohammad, Per Eriksson, Loreto Gesualdo, Duvuru Geetha, Matija Crnogorac, David Jayne, Susan L Hogan, Colin Geddes, Vladimir Tesar, Knut Aasarød, Mårten Segelmark
May 13, 2019
BACKGROUND: In anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis, antigen specificity varies between myeloperoxidase (MPO) and proteinase 3 (PR3). This has been reported to vary in relation to age...
Aged Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Antibodies Antineutrophil Cytoplasmic Antibody Specificity Biopsy Czech Republic Demography Female Geography glomerulonephritis Humans Italy Male Middle Aged Myeloblastin Norway Peroxidase Registries Serogroup Sweden United Kingdom United States
The HAVEN study-hydroxychloroquine in ANCA vasculitis evaluation-a multicentre, randomised, double-blind, placebo-controlled trial
Annastazia E Learoyd, Lauren Arnold, Fiona Reid, Nicholas Beckley-Hoelscher, Alina Casian, Shirish Sangle, Neil Morton, Louise Nel, Angela Cape, Susan John, Sangmi Kim, Dharshene Shivapatham, Raashid Luqmani, David Jayne, James Galloway, Abdel Douiri, David D'Cruz, HAVEN study group
Apr 06, 2023
BACKGROUND: Patients with non-severe ANCA-associated vasculitis (AAV) are often prescribed immunosuppressive medications that are associated with severe side effects and a reduced quality of life. There is an unmet need for...
Long-term maintenance rituximab for ANCA-associated vasculitis
Mark E McClure, Yajing Zhu, Rona M Smith, Seerapani Gopaluni, Joanna Tieu, Tasneem Pope, Karl Emil Kristensen, David RW Jayne, Jessica Barrett, Rachel B Jones
Nov 24, 2020
OBJECTIVES: Following a maintenance course of rituximab (RTX) for ANCA-associated vasculitis (AAV), relapses occur on cessation of therapy, and further dosing is considered. This study aimed to develop relapse and infection risk...
IoT Modeling for Digital Enterprises and Decision Analysis
Shaping IoT for digital enterprises involves integrating smart devices into business processes to achieve operational efficiencies and drive innovation. The importance of IoT modeling in enterprise decision-making cannot be...
Published by: IGI Global Scientific Publishing
|
|< |
< |
1 |